Despite the ever-decreasing risk posed by COVID-19, the FDA just authorized the first COVID breathalyzer to help hunt down the pesky virus.

According to an FDA news release, the InspectIR Covid-19 Breathalyzer is “about the size of a piece of carry-on luggage” and can detect COVID in “less than 3 minutes.” Wow!

Much like mRNA vaccines, the FDA utilized an Emergency Use Authorization to ram the product into usage, despite evidence of an emergency being severely lacking and a federal judge striking down the United States’ mask mandate — a clear indication that things are ready to go back to normal.

The news release continues, saying that the COVID breathalyzer isn’t intended to be used in people’s homes but in “environments where the patient specimen is both collected and analyzed, such as doctor’s offices, hospitals and mobile testing sites” by “qualified” professionals.

“The performance of the InspectIR COVID-19 Breathalyzer was validated in a large study of 2,409 individuals, including those with and without symptoms. In the study, the test was shown to have 91.2% sensitivity (the percent of positive samples the test correctly identified) and 99.3% specificity (the percent of negative samples the test correctly identified). The study also showed that, in a population with only 4.2% of individuals who are positive for the virus, the test had a negative predictive value of 99.6%, meaning that people who receive a negative test result are likely truly negative in areas of low disease prevalence,” the FDA writes.

Again, regardless of whether the breathalyzer is effective, there isn’t any apparent reason for its emergency authorization.

As previously reported by The Counter Signal, COVID death rates, hospitalizations, and ICU visits have plummeted worldwide.

In Ontario, as of April 5, those who have not received two doses of the COVID vaccine have a COVID death rate of 0.02 per capita, as do the fully vaccinated. However, those who have received booster shots have a COVID death rate of 0.03 per capita.

Additionally, those with a booster dose are also more likely to be infected with COVID-19 than any other group. Those with booster doses have 22.35 cases per capita, fully vaccinated have 15.47 cases per capita, and partially vaccinated or unvaccinated have 12.75 cases per capita.

Moreover, there are 184 unvaccinated patients in the hospital but not in the ICU. However, there are 671 fully vaccinated patients and 32 partially vaccinated patients.

These figures are extremely low for a province of over 10 million, and the situation is similar in the US.